MDGL insider transaction filings
MADRIGAL PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen MDGL transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Kelley Shannon T — General Counsel | Sale (S): 664 @ $514.97 | EDGAR |
| 2026-08-18 | 4 | REED JOHN C — Director | Grant/award (A): 647 @ $0 · Grant/award (A): 1,078 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Sibold William John — President and CEO, Director | Option exercise (M): 50,000 · Sale (S): 140 @ $542.75 · Sale (S): 110 @ $543.79 · Sale (S): 545 @ $544.71 · Sale (S): 275 @ $545.71 · Sale (S): 269 @ $547.08 · +6 more | EDGAR |
| 2026-06-18 | 4 | Taub Rebecca — Director | Grant/award (A): 454 @ $0 · Grant/award (A): 766 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Levy Richard S — Director | Grant/award (A): 454 @ $0 · Grant/award (A): 766 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | FOUSE JACQUALYN A — Director | Grant/award (A): 454 @ $0 · Grant/award (A): 766 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Daly James M — Director | Grant/award (A): 454 @ $0 · Grant/award (A): 766 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Brennan Daniel J. — Director | Grant/award (A): 404 @ $0 · Grant/award (A): 681 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 908 @ $0 · Grant/award (A): 908 @ $0 · Grant/award (A): 1,532 (derivative) @ $0 · Grant/award (A): 1,532 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Soergel David — Chief Medical Officer | Sale (S): 1,042 @ $495.74 | EDGAR |
| 2026-05-22 | 4 | Levy Richard S — Director | Sale (S): 40 @ $506.68 · Sale (S): 320 @ $508.24 · Sale (S): 151 @ $510.36 · Sale (S): 610 @ $511.40 · Sale (S): 439 @ $512.50 · Sale (S): 40 @ $512.97 · +6 more | EDGAR |
| 2026-05-18 | 4 | Soergel David — Chief Medical Officer | Sale (S): 844 @ $515.90 | EDGAR |
| 2026-03-06 | 4 | Dier Mardi — EVP and CFO | Grant/award (A): 5,215 @ $0 · Sale (S): 646 @ $431.94 · Sale (S): 40 @ $425.08 · Sale (S): 420 @ $426.86 · Sale (S): 80 @ $427.85 · Sale (S): 160 @ $429.00 · +8 more | EDGAR |
| 2026-03-06 | 4 | Sibold William John — President and CEO, Director | Grant/award (A): 14,995 @ $0 · Sale (S): 1,663 @ $431.94 · Grant/award (A): 18,743 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Kelley Shannon T — General Counsel | Grant/award (A): 4,017 @ $0 · Sale (S): 360 @ $431.94 · Grant/award (A): 5,022 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Huntsman Carole — Chief Commercial Officer | Grant/award (A): 3,989 @ $0 · Sale (S): 419 @ $431.94 · Grant/award (A): 4,986 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Taub Rebecca — Director | Sale (S): 491 @ $431.94 | EDGAR |
| 2026-03-06 | 4 | Soergel David — Chief Medical Officer | Grant/award (A): 4,374 @ $0 · Grant/award (A): 5,467 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Dier Mardi — EVP and CFO | Sale (S): 1,183 @ $427.21 | EDGAR |
| 2026-02-24 | 4 | Levy Richard S — Director | Option exercise (M): 2,500 @ $7.36 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Levy Richard S — Director | Option exercise (M): 4,000 @ $16.46 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Huntsman Carole — Chief Commercial Officer | Sale (S): 340 @ $492.42 · Sale (S): 570 @ $494.59 | EDGAR |
| 2026-01-26 | 4 | Sibold William John — President and CEO, Director | Sale (S): 1,577 @ $492.42 | EDGAR |
| 2026-01-26 | 4 | Taub Rebecca — Director | Sale (S): 647 @ $492.42 | EDGAR |
| 2026-01-20 | 4 | Kelley Shannon T — General Counsel | Sale (S): 263 @ $490.77 · Sale (S): 429 @ $501.40 | EDGAR |
| 2026-01-20 | 4 | Taub Rebecca — Director | Sale (S): 2,238 @ $490.77 | EDGAR |
| 2026-01-20 | 4 | Thakkar Rita — Chief Accounting Officer | Grant/award (A): 2,398 @ $0 · Grant/award (A): 1,826 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | FRIEDMAN PAUL A — Director | Option exercise (M): 280 @ $15.80 · Sale (S): 280 @ $551.24 · Option exercise (M): 280 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | FRIEDMAN PAUL A — Director | Option exercise (M): 24,520 @ $15.80 · Sale (S): 1,480 @ $511.98 · Sale (S): 1,094 @ $513.11 · Sale (S): 1,345 @ $514.68 · Sale (S): 1,996 @ $515.81 · Sale (S): 766 @ $516.84 · +24 more | EDGAR |
| 2026-01-13 | 4 | Taub Rebecca — Director | Option exercise (M): 240 @ $15.80 · Sale (S): 40 @ $545.79 · Sale (S): 200 @ $551.24 · Option exercise (M): 240 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Taub Rebecca — Director | Option exercise (M): 18,410 @ $15.80 · Sale (S): 960 @ $512.02 · Sale (S): 960 @ $513.12 · Sale (S): 937 @ $514.63 · Sale (S): 1,578 @ $515.82 · Sale (S): 521 @ $516.81 · +24 more | EDGAR |
| 2025-12-12 | 4 | FRIEDMAN PAUL A — Director | Option exercise (M): 24,800 @ $15.80 · Sale (S): 624 @ $547.75 · Sale (S): 535 @ $548.51 · Sale (S): 409 @ $549.99 · Sale (S): 4,316 @ $550.93 · Sale (S): 7,193 @ $551.67 · +5 more | EDGAR |
| 2025-12-12 | 4 | Taub Rebecca — Director | Option exercise (M): 18,650 @ $15.80 · Sale (S): 491 @ $547.76 · Sale (S): 369 @ $548.56 · Sale (S): 486 @ $550.07 · Sale (S): 4,723 @ $550.99 · Sale (S): 4,410 @ $551.85 · +6 more | EDGAR |
| 2025-12-04 | 4 | Sibold William John — President and CEO, Director | Option exercise (M): 50,000 · Sale (S): 2,400 @ $575.34 · Option exercise (M): 50,000 (derivative) | EDGAR |
| 2025-12-03 | 4 | Dier Mardi — EVP and CFO | Option exercise (M): 4,173 @ $251.63 · Sale (S): 320 @ $570.39 · Sale (S): 410 @ $571.99 · Sale (S): 354 @ $573.02 · Sale (S): 717 @ $574.00 · Sale (S): 120 @ $574.95 · +11 more | EDGAR |
| 2025-11-21 | 4 | Huntsman Carole — Chief Commercial Officer | Sale (S): 894 @ $550.97 · Sale (S): 144 @ $547.27 · Sale (S): 120 @ $548.71 · Sale (S): 40 @ $549.34 · Sale (S): 200 @ $552.38 · Sale (S): 40 @ $553.23 · +5 more | EDGAR |
| 2025-11-14 | 4 | Levy Richard S — Director | Option exercise (M): 2,500 @ $7.36 · Option exercise (M): 6,000 @ $16.46 · Sale (S): 146 @ $514.67 · Sale (S): 919 @ $515.64 · Sale (S): 645 @ $517.51 · Sale (S): 835 @ $518.53 · +12 more | EDGAR |
| 2025-11-07 | 4 | BATE KENNETH — Director | Option exercise (M): 5,470 @ $9.45 · Option exercise (M): 10,000 @ $303.79 · Option exercise (M): 1,105 @ $280.04 · Sale (S): 1,763 @ $480.24 · Sale (S): 3,259 @ $481.13 · Sale (S): 1,284 @ $482.41 · +11 more | EDGAR |
| 2025-09-09 | 4 | Sibold William John — President and CEO, Director | Sale (S): 7,279 @ $445.63 | EDGAR |
| 2025-08-21 | 4 | Sibold William John — President and CEO, Director | Sale (S): 6,485 @ $400.03 · Sale (S): 1,131 @ $401.00 | EDGAR |
| 2025-08-20 | 4 | BAKER BROS. ADVISORS LP — Director Baker Bros. Advisors (GP) LLC — Director BAKER FELIX — Director BAKER JULIAN — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director | Purchase (P): 2,460 @ $372.87 · Purchase (P): 26,704 @ $372.87 · Purchase (P): 675 @ $374.43 · Purchase (P): 7,325 @ $374.43 · Purchase (P): 480 @ $380.44 · Purchase (P): 5,209 @ $380.44 · +20 more | EDGAR |
| 2025-08-20 | 4 | BAKER BROS. ADVISORS LP — Director Baker Bros. Advisors (GP) LLC — Director BAKER FELIX — Director BAKER JULIAN — Director 667, L.P. — Director Baker Brothers Life Sciences LP — Director | Purchase (P): 177 @ $353.88 · Purchase (P): 1,923 @ $353.88 · Purchase (P): 84 @ $355 · Purchase (P): 916 @ $355 · Purchase (P): 767 @ $357.02 · Purchase (P): 8,328 @ $357.02 · +22 more | EDGAR |
| 2025-08-18 | 4 | Kelley Shannon T — General Counsel | Sale (S): 458 @ $358.66 · Sale (S): 126 @ $369.64 · Sale (S): 84 @ $370.06 · Sale (S): 84 @ $371.35 · Sale (S): 252 @ $372.44 · Sale (S): 68 @ $374.13 · +2 more | EDGAR |
| 2025-08-15 | 4 | BATE KENNETH — Director | Option exercise (M): 10,000 @ $16.46 · Sale (S): 2,317 @ $363.41 · Sale (S): 2,516 @ $364.24 · Sale (S): 2,567 @ $365.33 · Sale (S): 600 @ $366.14 · Sale (S): 1,104 @ $367.63 · +2 more | EDGAR |
| 2025-08-13 | 4 | Taub Rebecca — Director | Option exercise (M): 3,200 @ $9.45 · Sale (S): 2,980 @ $350.18 · Sale (S): 220 @ $351.02 · Option exercise (M): 43,263 @ $9.45 · Sale (S): 3,580 @ $350.87 · Sale (S): 2,870 @ $351.60 · +10 more | EDGAR |
| 2025-08-13 | 4 | FRIEDMAN PAUL A — Director | Option exercise (M): 129,172 @ $9.45 · Sale (S): 1,600 @ $358.23 · Sale (S): 455 @ $359.31 · Sale (S): 3,153 @ $360.27 · Sale (S): 1,754 @ $361.13 · Sale (S): 1,439 @ $362.29 · +13 more | EDGAR |
| 2025-08-13 | 4 | FRIEDMAN PAUL A — Director | Option exercise (M): 3,203 @ $9.45 · Sale (S): 2,903 @ $350.19 · Sale (S): 300 @ $351.04 · Option exercise (M): 43,605 @ $9.45 · Sale (S): 3,303 @ $350.93 · Sale (S): 3,202 @ $351.59 · +10 more | EDGAR |
| 2025-08-05 | 4 | Brennan Daniel J. — Director | Grant/award (A): 967 @ $0 · Grant/award (A): 1,705 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | Taub Rebecca — Director | Option exercise (M): 1,000 @ $9.45 · Sale (S): 1,000 @ $350.00 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2025-07-22 | 4 | FRIEDMAN PAUL A — Director | Option exercise (M): 1,400 @ $9.45 · Sale (S): 1,400 @ $350.03 · Option exercise (M): 1,400 (derivative) @ $0 | EDGAR |
Recent 8-K events — MADRIGAL PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-02-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MDGL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →